Press Releases

Press Releases

November 26, 2019
WOBURN, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke , Executive Chairman and Director of Replimune , will present and
November 14, 2019
BOSTON , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 3,678,031 shares of its common stock at a public offering
November 12, 2019
BOSTON , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of up to 5,000,000 shares of its common stock.
Displaying 1 - 10 of 21